UCL and Eisai Extend Neurodegenerative Disease Drug Discovery Partnership Through 2030
核心洞察
University College London and Eisai have signed a five-year extension to their drug discovery collaboration, continuing the partnership through 2030 to tackle Alzheimer's, Parkinson's, and ALS.
The alliance has already produced the anti-MTBR tau (搜索) antibody E2814, now in Phase II/III trials for dominantly inherited Alzheimer's disease (搜索) and Phase II for sporadic early AD.
Eight drug discovery projects have been supported through £10 million in investment to date, with further funding committed over the next five years.
University College London (UCL) and Eisai Co., Ltd. have signed a new agreement extending their drug discovery and development collaboration for an additional five years, taking the partnership through to 2030. The renewal, announced on July 2, 2026, reinforces a distinctive academia-industry model that combines UCL's neuroscience expertise with Eisai's pharmaceutical development capabilities to accelerate treatments for neurodegenerative diseases including Alzheimer's, Parkinson's, and Amyotrophic Lateral Sclerosis (搜索).
The alliance, first launched in 2012 and spearheaded by the UCL Translational Research Office (TRO) and the Faculty of Brain Sciences, has evolved into what both organizations describe as a partnership that goes beyond traditional collaboration frameworks. Over the past decade, it has created an ecosystem designed to accelerate translational research toward the clinic, nurture early-stage projects, and invest in talent development through jointly funded PhDs and long-term knowledge sharing.
A Track Record of Tangible Progress
The most notable outcome of the UCL–Eisai collaboration to date is the anti-MTBR tau (搜索) antibody E2814, discovered through joint research between the two organizations. The antibody is currently being evaluated in the DIAN-TU Phase II/III clinical trial for Dominantly Inherited Alzheimer's Disease (搜索) (DIAD), as well as a Phase II clinical trial for sporadic early Alzheimer's disease (Study 202).
In total, eight drug discovery projects targeting a variety of therapeutic pathways have been supported through £10 million in investment to date, with further investment committed over the next five years as part of the extension. The collaboration has also produced more than 30 scientific outputs, including publications and presentations, reflecting a commitment to sharing jointly acquired insights with the wider scientific community.
Strategic Focus for the Next Five Years
The renewed agreement launches with collaborative projects targeting novel therapeutic pathways and opens the door to UCL researchers across disciplines to bring forward innovative ideas for co-development. Over the next five years, the alliance will concentrate on advancing promising projects through recognized stage gates of the drug development pathway, actively seeking high-potential drug discovery projects, strengthening the neurodegeneration research talent pipeline through specialist scientist roles, enabling researchers to publish and present findings at international conferences, and sustaining close engagement across all levels of both organizations.
Professor Geraint Rees, UCL's Vice-Provost (Research, Innovation & Global Engagement), emphasized the rarity of such collaborations: "Long-term academic–industry partnerships of this depth are rare. The UCL–Eisai alliance shows what can be achieved addressing global health challenges when there is sustained alignment and trust. This five-year extension gives us the stability to deepen the science, accelerate translation from lab to market, and develop the next generation of research leaders."
Professor Tom Warner, Professor of Clinical Neurology at the UCL Queen Square Institute of Neurology and co-chair of the UCL-Eisai Joint Steering Committee, noted: "This renewal reflects the maturity of the collaboration and our shared ambition to take on challenging scientific questions in neurodegenerative disease. The next phase enables us to progress promising research discoveries into therapies with a clear pathway towards patients."
Dr. Katsutoshi Ido, Eisai's Chief Scientific Officer and co-chair of the Joint Steering Committee, highlighted the unique strengths of the partnership: "What distinguishes the collaboration with UCL is the depth of neuroscience expertise and the ability to connect early discovery with patient benefit. The Translational Research Office plays an essential role in supporting the partnership, and by working closely together we can more effectively advance promising research towards new treatments for patients."
Broader UK Commitment
The partnership extension coincides with Eisai's announcement of a strategic investment at its manufacturing site in Hatfield, Hertfordshire, supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions. This investment underscores Eisai's long-term commitment to strengthening its relationship with the United Kingdom and complements the academic collaboration with UCL.